Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 6 (June)

1. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.
   Lancet Oncol, 8(6): 475-87. [Abstract] [Full-text]
2. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
   Cancer Res, 67(11): 5498-504. [Abstract] [Full-text]
3. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus.
   Cancer Res, 67(11): 5434-42. [Abstract] [Full-text]
4. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.
   Cancer Res, 67(11): 5318-27. [Abstract] [Full-text]
5. Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer.
   Cancer Res, 67(11): 5221-30. [Abstract] [Full-text]
6. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
   Cancer Res, 67(11): 5117-25. [Abstract] [Full-text]
7. Inference on the limiting false discovery rate and the p-value threshold parameter assuming weak dependence between gene expression levels within subject.
   Stat Appl Genet Mol Biol, 6: Article14. [Abstract] [Full-text]
8. Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: creation of digitally reconstructed radiographs.
   Int J Radiat Oncol Biol Phys, 68(3): 903-11. [Abstract] [Full-text]
9. A study of image-guided intensity-modulated radiotherapy with fiducials for localized prostate cancer including pelvic lymph nodes.
   Int J Radiat Oncol Biol Phys, 68(3): 898-902. [Abstract] [Full-text]
10. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer.
    Int J Radiat Oncol Biol Phys, 68(3): 892-7. [Abstract] [Full-text]
11. Intensity-modulated radiotherapy using implanted fiducial markers with daily portal imaging: assessment of prostate organ motion.
    Int J Radiat Oncol Biol Phys, 68(3): 912-9. [Abstract] [Full-text]
12. What dose of external-beam radiation is high enough for prostate cancer?
    Int J Radiat Oncol Biol Phys, 68(3): 682-9. [Abstract] [Full-text]
13. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome.
    Int J Radiat Oncol Biol Phys, 68(3): 699-706. [Abstract] [Full-text]
14. Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 68(3): 690-8. [Abstract] [Full-text]
15. Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells.
    J Cell Physiol, 212(2): 298-306. [Abstract] [Full-text]
16. Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study.
    J Gen Intern Med, 22(7): 901-7. [Abstract] [Full-text]
17. Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies.
    Future Oncol, 3(3): 329-41. [Abstract] [Full-text]
18. Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function.
    J Clin Invest, 117(6): 1647-57. [Abstract] [Full-text]
19. Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate.
    Nat Clin Pract Urol, 4(6): 321-32. [Abstract] [Full-text]
20. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
    Am J Clin Oncol, 30(3): 234-8. [Abstract] [Full-text]
21. Dosimetry of an extracapsular anulus following permanent prostate brachytherapy.
    Am J Clin Oncol, 30(3): 228-33. [Abstract] [Full-text]
22. Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma.
    J Natl Cancer Inst, 99(11): 868-80. [Abstract] [Full-text]
23. Modulating paclitaxel bioavailability for targeting prostate cancer.
    Bioorg Med Chem, 15(14): 4973-84. [Abstract] [Full-text]
24. NMR-based metabolomics approach to target biomarkers for human prostate cancer.
    Expert Rev Proteomics, 4(3): 389-400. [Abstract] [Full-text]
25. Prostate cancer mortality predictions for Ireland up to 2015.
    Eur J Cancer Prev, 16(4): 328-33. [Abstract] [Full-text]
26. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.
    J Clin Oncol, 25(17): 2420-5. [Abstract] [Full-text]
27. Highly efficient cationic hydroxyethylated cholesterol-based nanoparticle-mediated gene transfer in vivo and in vitro in prostate carcinoma PC-3 cells.
    J Control Release, 120(1): 122-30. [Abstract] [Full-text]
28. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Cancer, 109(12): 2432-8. [Abstract] [Full-text]
29. The quality of surgical pathology care for men undergoing radical prostatectomy in the U.S.
    Cancer, 109(12): 2445-53. [Abstract] [Full-text]
30. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase.
    Cancer Lett, 253(1): 124-30. [Abstract] [Full-text]
31. Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995-2004.
    Am J Epidemiol, 166(1): 71-8. [Abstract] [Full-text]
32. Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.
    Cancer Chemother Pharmacol, 60(3): 341-9. [Abstract] [Full-text]
33. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha.
    Biochim Biophys Acta, 1771(7): 883-92. [Abstract] [Full-text]
34. Ejaculatory disorders may affect screening for prostate cancer.
    J Urol, 178(1): 232-7; discussion 237-8. [Abstract] [Full-text]
35. Interstitial photodynamic therapy of the canine prostate using intra-arterial administration of photosensitizer and computerized pulsed light delivery.
    J Urol, 178(1): 308-13. [Abstract] [Full-text]
36. Under diagnosis and over diagnosis of prostate cancer.
    J Urol, 178(1): 88-92. [Abstract] [Full-text]
37. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%.
    J Urol, 178(1): 120-4. [Abstract] [Full-text]
38. Decrease in racial disparities in the staging evaluation for prostate cancer after publication of staging guidelines.
    J Urol, 178(1): 82-7; discussion 87. [Abstract] [Full-text]
39. Is routine digital rectal examination required for the followup of prostate cancer?
    J Urol, 178(1): 115-9. [Abstract] [Full-text]
40. Does the intrarectal instillation of lidocaine gel before periprostatic neurovascular bundle block during transrectal ultrasound guided prostate biopsies improve analgesic efficacy? A prospective, randomized trial.
    J Urol, 178(1): 103-6. [Abstract] [Full-text]
41. Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies.
    J Urol, 178(1): 111-4. [Abstract] [Full-text]
42. Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml.
    J Urol, 178(1): 93-7; discussion 97. [Abstract] [Full-text]
43. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
    J Urol, 178(1): 107-9; discussion 110. [Abstract] [Full-text]
44. Clinical judgment analysis of the parameters used by consultant urologists in the management of prostate cancer.
    J Urol, 178(1): 98-102. [Abstract] [Full-text]
45. Age, health, and education determine supportive care needs of men younger than 70 years with prostate cancer.
    J Clin Oncol, 25(18): 2560-6. [Abstract] [Full-text]
46. Prostate-specific antigen in the early detection of prostate cancer.
    CMAJ, 176(13): 1853-8. [Abstract] [Full-text]
47. Umbilical metastasis from prostate carcinoma (Sister Mary Joseph's nodule): a case report and review of literature.
    J Cutan Pathol, 34(7): 581-3. [Abstract] [Full-text]
48. Prostate cancer progression and survival in BRCA2 mutation carriers.
    J Natl Cancer Inst, 99(12): 929-35. [Abstract] [Full-text]
49. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity.
    Anticancer Drugs, 18(7): 809-16. [Abstract] [Full-text]
50. Psychometric properties of a prostate cancer radiation late toxicity questionnaire.
    Health Qual Life Outcomes, 5: 29. [Abstract] [Full-text]
51. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Mol Pharmacol, 72(1): 73-85. [Abstract] [Full-text]
52. Synchronous male breast cancer and carcinoma of prostate in 90-year-old male, presented with spinal cord compression and multiple spine lytic lesions.
    Breast J, 13(4): 410-2. [Abstract] [Full-text]
53. The impact of birth weight on prostate cancer incidence and mortality in a population-based study of men born in 1913 and followed up from 50 to 85 years of age.
    Prostate, 67(11): 1247-54. [Abstract] [Full-text]
54. Androgens and prostate cancer risk: a prospective study.
    Prostate, 67(11): 1230-7. [Abstract] [Full-text]
55. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
    Prostate, 67(11): 1219-29. [Abstract] [Full-text]
56. Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis.
    Prostate, 67(11): 1202-10. [Abstract] [Full-text]
57. Effect of metabolic inhibitors on ATP and citrate content in PC3 prostate cancer cells.
    Prostate, 67(11): 1211-8. [Abstract] [Full-text]
58. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
    Prostate, 67(11): 1182-93. [Abstract] [Full-text]
59. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide.
    Prostate, 67(11): 1194-201. [Abstract] [Full-text]
60. A population study of neutering status as a risk factor for canine prostate cancer.
    Prostate, 67(11): 1174-81. [Abstract] [Full-text]
61. Exploration of target molecules for prostate cancer gene therapy.
    Prostate, 67(11): 1163-73. [Abstract] [Full-text]
62. Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer.
    Prostate, 67(11): 1143-51. [Abstract] [Full-text]
63. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
    Prostate, 67(11): 1152-62. [Abstract] [Full-text]
64. Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study.
    J Clin Pathol, 60(7): 773-80. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.